

Andrew C Chan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1208235/publications.pdf>

Version: 2024-02-01

39
papers

4,650
citations

257450

24
h-index

361022

35
g-index

40
all docs

40
docs citations

40
times ranked

6299
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic antibodies for autoimmunity and inflammation. <i>Nature Reviews Immunology</i> , 2010, 10, 301-316.	22.7	748
2	Essential role for ZAP-70 in both positive and negative selection of thymocytes. <i>Nature</i> , 1995, 376, 435-438.	27.8	516
3	Importance of Cellular Microenvironment and Circulatory Dynamics in B Cell Immunotherapy. <i>Journal of Immunology</i> , 2005, 174, 817-826.	0.8	491
4	A biosynthetic pathway for anandamide. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 13345-13350.	7.1	396
5	PEST Domain-Enriched Tyrosine Phosphatase (PEP) Regulation of Effector/Memory T Cells. <i>Science</i> , 2004, 303, 685-689.	12.6	355
6	B CELL IMMUNOBIOLOGY IN DISEASE: Evolving Concepts from the Clinic. <i>Annual Review of Immunology</i> , 2006, 24, 467-496.	21.8	349
7	Requirement for B Cell Linker Protein (BLNK) in B Cell Development. <i>Science</i> , 1999, 286, 1949-1954.	12.6	276
8	B cell targeted therapies in human autoimmune diseases: an updated perspective. <i>Immunological Reviews</i> , 2010, 237, 264-283.	6.0	210
9	The Autoimmunity-Associated Gene PTPN22 Potentiates Toll-like Receptor-Driven, Type 1 Interferon-Dependent Immunity. <i>Immunity</i> , 2013, 39, 111-122.	14.3	172
10	NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22. <i>Journal of Clinical Investigation</i> , 2016, 126, 1783-1800.	8.2	171
11	Disruption of T cell signaling networks and development by Grb2 haploid insufficiency. <i>Nature Immunology</i> , 2001, 2, 29-36.	14.5	156
12	<i>PTPN22</i> Deficiency Cooperates with the CD45 E613R Allele to Break Tolerance on a Non-Autoimmune Background. <i>Journal of Immunology</i> , 2009, 182, 4093-4106.	0.8	117
13	<i>PTPN22</i> regulates NLRP3-mediated IL1B secretion in an autophagy-dependent manner. <i>Autophagy</i> , 2017, 13, 1590-1601.	9.1	90
14	Thermodynamic Study of the Binding of the Tandem-SH2 Domain of the Syk Kinase to a Dually Phosphorylated ITAM Peptide: Evidence for Two Conformers. <i>Biochemistry</i> , 1999, 38, 5024-5033.	2.5	56
15	Regulation of T Cell Receptor Signaling by DENND1B in T H 2 Cells and Allergic Disease. <i>Cell</i> , 2016, 164, 141-155.	28.9	53
16	Toso regulates the balance between apoptotic and nonapoptotic death receptor signaling by facilitating RIP1 ubiquitination. <i>Blood</i> , 2011, 118, 598-608.	1.4	45
17	Dusp5 negatively regulates IL-3-mediated eosinophil survival and function. <i>EMBO Journal</i> , 2015, 34, 218-235.	7.8	45
18	Accumulation of 4-1BBL+ B cells in the elderly induces the generation of granzyme-B+ CD8+ T cells with potential antitumor activity. <i>Blood</i> , 2014, 124, 1450-1459.	1.4	41

#	ARTICLE	IF	CITATIONS
19	In Search of Magic Bullets: The Golden Age of Immunotherapeutics. <i>Cell</i> , 2014, 157, 227-240.	28.9	40
20	Personalizing medicine for autoimmune and inflammatory diseases. <i>Nature Immunology</i> , 2013, 14, 106-109.	14.5	35
21	Requirement for Tyrosine Residues 315 and 319 within Î¶ Chain Associated Protein 70 for T Cell Development. <i>Journal of Experimental Medicine</i> , 2001, 194, 507-518.	8.5	34
22	Inefficient ZAP-70 Phosphorylation and Decreased Thymic Selection In Vivo Result from Inhibition of NF-Î±B/Rel. <i>Journal of Immunology</i> , 2001, 167, 5628-5635.	0.8	34
23	Administration of Anti-CD20 mAb Is Highly Effective in Preventing but Ineffective in Treating Chronic Graft-Versus-Host Disease While Preserving Strong Graft-Versus-Leukemia Effects. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1089-1103.	2.0	30
24	Autoimmunity linked protein phosphatase PTPN22 as a target for cancer immunotherapy. , 2020, 8, e001439.		30
25	Autoimmunity-associated protein tyrosine phosphatase PEP negatively regulates IFN-Î± receptor signaling. <i>Journal of Experimental Medicine</i> , 2015, 212, 1081-1093.	8.5	24
26	Regulation of thymocyte development: only the meek survive. <i>Current Opinion in Immunology</i> , 2003, 15, 199-203.	5.5	22
27	Stratified medicine in inflammatory disorders: From theory to practice. <i>Clinical Immunology</i> , 2015, 161, 11-22.	3.2	21
28	Surface receptor Toso controls B cell mediated regulation of T cell immunity. <i>Journal of Clinical Investigation</i> , 2018, 128, 1820-1836.	8.2	18
29	B cell immunotherapy in autoimmunity 2010 update. <i>Molecular Immunology</i> , 2011, 48, 1344-1347.	2.2	15
30	Rituximab's New Therapeutic Target: The Podocyte Actin Cytoskeleton. <i>Science Translational Medicine</i> , 2011, 3, 85ps21.	12.4	15
31	Protein tyrosine phosphatase non-receptor type 22 modulates colitis in a microbiota-dependent manner. <i>Journal of Clinical Investigation</i> , 2019, 129, 2527-2541.	8.2	15
32	30 Years of Biotherapeutics Development What Have We Learned?. <i>Annual Review of Immunology</i> , 2020, 38, 249-287.	21.8	11
33	Molecular and Genetic Insights into T-Cell Antigen Receptor Signaling. <i>Annals of the New York Academy of Sciences</i> , 1995, 766, 149-156.	3.8	9
34	B cell-mediated regulatory mechanisms control tumor-promoting intestinal inflammation. <i>Cell Reports</i> , 2022, 40, 111051.	6.4	7
35	Ocrelizumab: A New Therapeutic Paradigm for Multiple Sclerosis. <i>Biochemistry</i> , 2018, 57, 474-476.	2.5	2
36	Interview: Experiences targeting B cells for the treatment of multiple sclerosis. <i>Immunotherapy</i> , 2014, 6, 127-130.	2.0	1

#	ARTICLE	IF	CITATIONS
37	Defining Molecular Targets for Drug Design: Synergism Between Academia and Industry. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2005, 40, S47.	1.8	0
38	A golden era of opportunity in immunotherapy discovery and development. <i>Immunological Reviews</i> , 2008, 223, 5-6.	6.0	0
39	B-cell function modulation in multiple sclerosis: a new therapeutic paradigm. <i>Future Neurology</i> , 2014, 9, 23-26.	0.5	0